BioLight Life Sciences Ltd. (TLV:BOLT)
Israel · Delayed Price · Currency is ILS · Price in ILA 522.00
-7.30 (-1.38%)
Aug 25, 2025, 4:08 PM IDT
BioLight Life Sciences Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 0.17 | 0.22 | 0.12 | 0.06 | 0 | 0.03 | Upgrade | |
Revenue Growth (YoY) | 6.96% | 85.59% | 87.30% | 2000.00% | -90.32% | - | Upgrade |
Gross Profit | 0.17 | 0.22 | 0.12 | 0.06 | 0 | 0.03 | Upgrade |
Selling, General & Admin | 7.27 | 6.66 | 6.25 | 6.86 | 6.27 | 6.66 | Upgrade |
Research & Development | 4.6 | 3.67 | 4.52 | 3.53 | 4.34 | 3.99 | Upgrade |
Other Operating Expenses | - | - | - | - | - | 0.77 | Upgrade |
Operating Expenses | 11.87 | 10.34 | 10.77 | 10.39 | 10.61 | 11.42 | Upgrade |
Operating Income | -11.7 | -10.12 | -10.65 | -10.32 | -10.6 | -11.39 | Upgrade |
Interest Expense | -0.08 | -0.08 | -0.08 | -0.07 | -0.02 | -0.04 | Upgrade |
Interest & Investment Income | 0.02 | 0.06 | 0.26 | 0.01 | 0.07 | 0.3 | Upgrade |
Earnings From Equity Investments | -0.35 | -0.29 | -0.39 | -0.63 | -0.28 | -0.38 | Upgrade |
Currency Exchange Gain (Loss) | -0.31 | -0.31 | 0.04 | 0.57 | -0.88 | -1.19 | Upgrade |
Other Non Operating Income (Expenses) | -0.17 | -0.17 | -0.96 | 0.3 | -0.27 | 0.03 | Upgrade |
EBT Excluding Unusual Items | -12.59 | -10.92 | -11.77 | -10.14 | -11.98 | -12.67 | Upgrade |
Gain (Loss) on Sale of Investments | -2.55 | 2.49 | -15.72 | 1.45 | 10.07 | -1.43 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.07 | Upgrade |
Pretax Income | -15.14 | -8.42 | -27.49 | -8.69 | -1.91 | -14.04 | Upgrade |
Income Tax Expense | - | - | - | - | -1.57 | 0.14 | Upgrade |
Earnings From Continuing Operations | -15.14 | -8.42 | -27.49 | -8.69 | -0.34 | -14.17 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | -0.92 | Upgrade |
Net Income to Company | -15.14 | -8.42 | -27.49 | -8.69 | -0.34 | -15.09 | Upgrade |
Minority Interest in Earnings | 2.42 | 1.28 | 1.47 | 0.84 | 0.72 | 1.7 | Upgrade |
Net Income | -12.72 | -7.14 | -26.02 | -7.85 | 0.38 | -13.38 | Upgrade |
Net Income to Common | -12.72 | -7.14 | -26.02 | -7.85 | 0.38 | -13.38 | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
Shares Change (YoY) | 0.13% | 0.29% | 1.70% | -0.41% | 0.94% | - | Upgrade |
EPS (Basic) | -2.73 | -1.53 | -5.60 | -1.72 | 0.08 | -2.95 | Upgrade |
EPS (Diluted) | -2.73 | -1.53 | -5.60 | -1.72 | 0.08 | -2.95 | Upgrade |
Free Cash Flow | - | -11.02 | -10.99 | -9.57 | -10.63 | -13.49 | Upgrade |
Free Cash Flow Per Share | - | -2.37 | -2.37 | -2.10 | -2.32 | -2.97 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -6921.89% | -4619.64% | -9026.27% | -16384.13% | -353433.33% | -36751.61% | Upgrade |
Profit Margin | -7524.26% | -3261.19% | -22050.85% | -12455.56% | 12733.33% | -43167.74% | Upgrade |
Free Cash Flow Margin | - | -5032.88% | -9315.25% | -15193.65% | -354333.33% | -43529.03% | Upgrade |
EBITDA | -11.63 | -10.06 | -10.6 | -9.73 | -10.07 | -10.84 | Upgrade |
D&A For EBITDA | 0.06 | 0.06 | 0.05 | 0.59 | 0.53 | 0.56 | Upgrade |
EBIT | -11.7 | -10.12 | -10.65 | -10.32 | -10.6 | -11.39 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.